Clovis Oncology Launches Rubraca (rucaparib) for Women with Relapsed Ovarian Cancer in Germany

 Clovis Oncology Launches Rubraca (rucaparib) for Women with Relapsed Ovarian Cancer in Germany

Clovis Oncology Launches Rubraca (rucaparib) for Women with Relapsed Ovarian Cancer in Germany

Shots:

  • Clovis Oncology’s Rubraca (rucaparib) enters in EU with its first launch in Germany and is approved for both treatment and maintenance treatment of ovarian cancer in women
  • The launch is based on P-III ARIEL3 study assessing Rubraca (rucaparib) vs PBO in 564 women with relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer in response to platinum-based chemotherapy in ratio 2:1
  • Rubraca (600mg, q2d,) is an oral PARP inhibitor used as monothx & as combination for multiple tumors with its expected launch in other EU countries in H2’19 & 2020

Click here to read full press release/ article | Ref: Clovis Oncology | Image: Condit

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post